Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Increase in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 1,790,000 shares, an increase of 39.8% from the April 15th total of 1,280,000 shares. Based on an average daily volume of 335,100 shares, the short-interest ratio is currently 5.3 days. Approximately 3.0% of the shares of the company are short sold.

Centessa Pharmaceuticals Price Performance

CNTA stock traded down $0.58 during mid-day trading on Friday, reaching $8.97. 68,436 shares of the company traded hands, compared to its average volume of 266,732. Centessa Pharmaceuticals has a 52-week low of $3.96 and a 52-week high of $12.45. The company has a market capitalization of $903.64 million, a P/E ratio of -5.71 and a beta of 1.44. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.00 and a quick ratio of 8.00. The company has a fifty day moving average price of $10.54 and a 200-day moving average price of $8.77.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. The firm had revenue of $6.85 million for the quarter. As a group, analysts anticipate that Centessa Pharmaceuticals will post -1.83 earnings per share for the current year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 51,160 shares of the business's stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the sale, the insider now directly owns 71,525 shares in the company, valued at $849,717. The sale was disclosed in a filing with the SEC, which is accessible through this link. 11.54% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its stake in Centessa Pharmaceuticals by 69.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company's stock worth $122,000 after acquiring an additional 4,423 shares during the last quarter. Quarry LP bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $48,000. Jump Financial LLC purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. Trexquant Investment LP purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $114,000. Finally, Acadian Asset Management LLC bought a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth $330,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets reissued an "outperform" rating and issued a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.